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Abstract: Quality of life (QOL) has become an important consideration in the care of patients 
with bone metastases as prevalence, incidence and patient survival are on the rise. As a result, 
more interventional studies now measure patient’s QOL as a meaningful endpoint. However, 
well-developed bone metastases speciﬁ  c quality of life instruments are lacking. A literature review 
was conducted to better understand the nature of QOL instruments used in bone metastases trials. 
A total of 47 articles evaluating QOL in patients with bone metastases were identiﬁ  ed. Twenty-
ﬁ  ve different instruments were used to evaluate QOL with study-designed questionnaires and the 
EORTC QLQ-C30 being most commonly employed. Many studies used more than one scale or 
instrument to measure QOL. This makes it difﬁ  cult to compare QOL in bone metastases patients 
across studies and come to any formal conclusions. Therefore, this review demonstrates the need 
to develop a bone module that can be used across countries in future clinical trials.
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Introduction
Bone metastases are a signiﬁ  cant cause of morbidity and skeletal complications in 
many cancer patients. Primary tumors of the breast and prostate are the most common 
to metastasize to the bone, with a post-mortem incidence of approximately 70% 
(Coleman 2006). Primary tumors of the lung, thyroid, and kidney also metastasize 
to the bone with a post-mortem incidence of approximately 30% to 40% (Perez et al 
2004). The morbidity associated with metastatic bone diseases includes pain, hyper-
calcemia, pathological fractures, spinal instability, cord compression, and immobility 
(Manoso and Healey 2005).
Treatment options for bone metastases have expanded to include orthopedic inter-
ventions, newer generations of bisphosphonates and systemic therapy. With recent 
advances in effective treatment options and a multidisciplinary approach to cancer 
management, the survival of patients with bone metastases has increased. Consequently, 
an increasing number of people are living longer years with bone metastases and the 
need to maximize their quality of life (QOL) during these years is essential.
The World Health Organization deﬁ  nes health as “a state of complete physical, mental 
and social well-being and not merely the absence of disease or inﬁ  rmity” (World Health 
Organization 1948). This multidimensional deﬁ  nition of health has encouraged health 
care professionals and clinical trials investigators to incorporate all aspects of health in 
treatment. Consequently, an increasing emphasis has been placed on QOL as an outcome 
measurement endpoint in clinical trials. Over the last three decades there has been an 
explosion of QOL studies in medical literature. A Medline search using “quality of life” 
as a keyword reveals a signiﬁ  cant increase in the number of articles related to the topic 
over a period of 30 years, from 32 in 1973 to 5444 in 2004 (Siddiqui et al 2006).
Quality of life has become an important consideration in the management of bone 
metastases. QOL instruments help health care professionals to better understand the Journal of Pain Research 2008:1 50
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impact of new or existing treatments on various aspects of a 
patient’s life. Recently, site-speciﬁ  c QOL instruments have 
been developed as the issues plaguing cancer patients differ 
depending on their symptoms, course of treatment and future 
outlook. However, bone metastases speciﬁ  c QOL instru-
ments are lacking. The objective of this study was to review 
the QOL instruments that have been used in previous bone 
metastases trials.
Methods
A literature review was conducted in July 2006 using Medline 
(PubMed) from OVID registries for any studies measuring 
QOL in patients with bone metastases from 1966 to June 2006. 
The keywords used were “bone neoplasms”, “bone metastases” 
and “quality of life (QOL)”. Studies involving a patient cohort 
with metastases sites other than the bone were excluded in 
hopes to better understand the speciﬁ  city of instruments used 
in bone metastases trials alone. Any individual case reports, 
qualitative studies or review articles were also excluded.
Results
Forty-seven trials measuring QOL in patients with bone 
metastases were identiﬁ  ed. Table 1 presents the patient 
population number, treatment setting, and assessment tools 
in each study. Of the 47 studies, 18 included bisphosphonate 
treatments, 12 included surgical/orthopedic interventions, 
8 involved radiotherapy and 9 investigated other treatment 
options for patients with bone metastases (Table 2). The 
47 studies involved a total of 10,844 patients. The number 
of participants in the studies ranged from 7–1,171 with a 
median number 85.
A total of 24 different instruments were used to evaluate 
QOL including pain assessment scales, validated QOL instru-
ments, and study-designed questionnaires (Table 3). The 
number of instruments used in each study varied. Excluding 
pain measurements other than the BPI or PPI, the number 
of instruments used to measure QOL ranged from 1 to 4. Of 
the 47 studies, 21 (45%), 17 (36%), 7 (15%), and 2 (4%) 
of the studies used 1, 2, 3, and 4 instruments, respectively. 
Most studies employed study-designed questionnaires 
(n = 10, 21%) or the European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire version 
3 (EORTC QLQ-C30) (n = 10, 21%) as assessment tools.
Summary of quality of life instruments 
employed
The EORTC QLQ-C30 is a validated questionnaire used to 
evaluate the quality of life of cancer patients. It consists of 
30 questions incorporating ﬁ  ve functional scales (physical 
functioning, role functioning, cognitive functioning, emo-
tional functioning and social functioning), 3 symptom scales 
(fatigue, pain, and nausea and vomiting), and a global health 
scale. The remaining items assess other symptoms commonly 
reported by cancer patients (dyspnea, appetite loss, sleep 
disturbance, constipation and diarrhea), as well as perceived 
ﬁ  nancial difﬁ  culties associated with the disease and its 
treatment (Aaronson et al 1993). Ten out of the 47 studies 
used the EORTC QLQ-C30 (Kristensen et al 1999; Osoba 
et al 1999; DiLorenzo et al 2002; Smeland et al 2003; Body 
et al 2004; Collette et al 2004; Diel et al 2004; Jenlev et al 
2005; Wardley et al 2005; Kaasa et al 2006). The EORTC 
QLQ-C30 is also supplemented by site-speciﬁ  c modules such 
as the BR 23 as used by Wardley and colleagues (2005). The 
BR23 consists of 23 breast cancer-speciﬁ  c questions focus-
ing on the side effects of therapy, body image, sexuality and 
outlook for the future.
Study-designed assessments were used in 10 publications 
(van Holtzen-Verzantvoort et al 1991; van Holtzen-
Verzantvoort et al 1993; Creswell 1995; van Holtzen-
Verzantvoort et al 1996; Nair et al 1999; Osoba et al 1999; 
Schoeggl et al 2002; Hirabayashi et al 2003; van den Hout 
et al 2003; Anselmetti et al 2004). For example, Cressewell 
and colleagues (1995) did not use the EORTC QLQ-C30 or 
any other established questionnaires but did design a disease-
speciﬁ  c questionnaire addressing patients’ perspectives on 
physical activity limitations and treatment expectations. This 
suggested the lack of a bone metastases-speciﬁ  c instrument. 
However, the use of a variety of study-designed assessments 
does not allow for outcome comparison between studies.
The Functional Assessment of Cancer Therapy-General 
questionnaire (FACT-G) is a multidimensional questionnaire 
developed and validated in cancer patients to measure the 
changes in the 4 main domains of the quality of life: physical 
well-being (7 items), social/family well-being (7 items), emo-
tional well-being (6 items) and functional well-being (7 items) 
(Cella et al 1993). As with the EORTC QLQ-C30, the FACT-G 
is also designed for cancer patients in general. The FACT-G 
was used to evaluate QOL in 5 articles (Vitale et al 2001; Saad 
et al 2002; Vogel et al 2004; Weinfurt et al 2004, 2005).
The Edmonton Symptom Assessment System (ESAS) is 
a validated 9-item, patient-rated, symptom verbal rating scale 
with domains in global pain, nausea, tiredness, depression, 
anxiety, drowsiness, appetite, sense of well-being, and short-
ness of breath (Bruera et al 1991). The ESAS was designed to 
assess the multidimensional nature of quality of life speciﬁ  c 
to palliative care and has been demonstrated to be valid and Journal of Pain Research 2008:1 51
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reliable in patients with terminal cancer (Bruera et al 1991). 
The ESAS was used in 4 of the articles (Wai et al 2003; 
Chow et al 2004; Mancini et al 2004; Cheung et al 2006).
The Rotterdam Symptom Checklist (RSCL), used in 
4 of the articles (Purohit et al 1994; Popev et al 1997; 
Vinholes et al 1997; Steenland et al 1999), is a tool used to 
measure the psychological and physical distress in cancer 
patients. The RSCL consists of 38 items covering 3 domains: 
physical symptoms, psychological symptoms and activities 
of daily living (de Haes et al 1990).
The Brief Pain Inventory (BPI) evaluates patient’s worst, 
average and current pain, analgesic consumption and the pain 
relief from medication. Pain interference with daily living is 
evaluated with questions concerning general activity, mood, 
walking ability, normal work, relations with other people, 
sleep, and enjoyment of life (Cleeland and Ryan 1994). 
While the BPI is an excellent measure of pain intensity and 
interference, it is not a complete measurement of overall QOL 
and is often accompanied by other tools. Four articles in this 
review used the BPI to measure quality of life (Callstrom 
et al 2002; Saad et al 2002; Pistevou-Gompaki et al 2004; 
Weinfurt et al 2005).
The EuroQol classiﬁ  cation system (EQ-5D) is a generic 
health-related QOL instrument, designed for cost-utility anal-
yses and comparisons of therapeutic effects across different 
diseases. The EQ-5D has ﬁ  ve attributes (mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression) 
(Brooks et al 2003). Three articles used the EQ-5D (Saad 
et al 2002; van den Hout et al 2003; Weinfurt et al 2005).
The Townsend Functional Assessment Scale (TFAS) is 
a classiﬁ  cation of a patient’s functional capabilities using 
four categories: normal pain-free function, normal func-
tion but with pain, signiﬁ  cantly limited function requiring 
prostheses, and nonfunctional (Townsend et al 1994). Three 
articles used the TFAS (Wai et al 2003; Chow et al 2004; 
Cheung et al 2006).
The Frankel classiﬁ  cation system was developed by the 
American Spinal Injury Association in spinal cord injuries 
(Frankel 1969). Three studies used the Frankel classiﬁ  cation 
to measure neurological status of bone metastases patients in 
the surgery setting to categorize the degree of motor, sensory, 
and autonomic involvement (Hirabyashi et al 2001; Okuyama 
et al 1999; Walsh et al 1997).
The following instruments were used in two studies each:
The Functional Living Index: Cancer (FLIC) is a 
validated QOL instrument used to evaluate the effect of the 
symptoms of cancer and its treatment on functional ability in 
all areas of life (Schipper et al 1984). The Hospital Anxiety Journal of Pain Research 2008:1 55
Quality of life measurement in bone metastases
Table 2 Study treatment settings
Treatment Number of studies
Bisphosphonates 18 (38%)
Surgical and orthopedic intervention 12 (26%)
Radiotherapy 8 (17%)
Other 9 (19%)
Systemic therapy 4 (9%)
Radiofrequency abalation 2 (4%)
Skeletal events evaluation 1 (2%)
Pain 1 (2%)
Total 47
and Depression Scale (HADS) consists of 14 statements 
relating to anxiety and depression based on patient expe-
rience over the past week (Zigmond and Snaith 1983). 
The Musculoskeletal Tumor Society (MSTS) functional 
assessment form measures functional outcomes in patients 
with musculoskeletal tumors. The evaluation scores are 
determined by the restriction in activities (actual or pro-
hibited) and the effect of these restrictions on the patient’s 
lifestyle (Enneking 1987; Enneking et al 1993). The Short 
Form-36 (SF-36) is a validated generic tool used to evaluate 
overall health status in eight domains consisting of: physical 
functioning, role limitations secondary to physical problems, 
bodily pain, general health, vitality, social functioning, role 
limitations because of emotional problems and mental health 
(Ware 1993). The Spitzer’s quality of life index has ﬁ  ve items 
concerning activity, daily living, health, support and outlook 
each rates according the verbal description that most closely 
reﬂ  ects the patient’s status (Spitzer et al 1981). The Present 
Pain Intensity (PPI) is a six-point pain intensity scale of the 
McGill-Melzack Pain Questionnaire (Melzack 1975).
The following measurements were used in one study each:
The Toronto Extremity Salvage Score (TESS) evaluates 
physical disability in patients treated for extremity tumors. 
The TESS includes 30 items on activity limitations in daily 
life such as restrictions in body movement, mobility, self-
care, and performance of daily tasks (Davis et al 1996). The 
Allan Scoring System is used to assess pain, independence 
and ambulation ability (Allan et al 1995). The Aboulaﬁ  a 
Scoring System scale is a scoring system for saddle recon-
struction and is used to evaluate clinical function in patients 
post-operatively (Aboulaﬁ  a et al 1995). The fatigue question-
naire was developed for a hospital based study of chronic 
fatigue syndrome consisting of 11 items including domains 
such as physical and mental aspects of fatigue, duration 
of fatigue, percent of time the respondent felt fatigue, and 
muscle pain during rest and exercise (Kaasa et al 2006). 
The Prostate Cancer Speciﬁ  c Quality of Life Instrument 
(PROSQOLI) uses a series of nine linear analog scale related 
to pain, physical activity, fatigue, appetite, constipation, 
passing urine, family/marriage relationships, mood, and 
overall well being (Ernst et al 2003).
Other endpoints utilized especially in studies investigat-
ing bisphosphonates include the monitoring the occurrence 
of skeletal related events such as hypercalcemia, pathologi-
cal fractures, spinal cord compression, use of surgery and 
radiation.
Pain assessment
Thirty-nine of the studies measured the intensity and fre-
quency of bony pain, its impact on function and physical 
activities, and analgesic consumption. Of the 8 studies that 
did not speciﬁ  cally evaluate pain, 6 utilized validated QOL 
instruments (EORTC QLQ-C30, FACT-G, FLIC, SF-36, 
Table 3 Frequency of instruments used in clinical trials measuring 
quality of life in patients with bone metastases
Instrument Frequency
ECOG (WHO) Performance Scores 15
Study-designed assessment 10
EORTC QLQ-C30 10
Functional Assessment of Cancer 
Therapy – General (FACT-G)
5
Rotterdam Symptom Checklist (RSCL) 4
Karnofsky Performance Score (KPS) 4
Edmonton Symptom Assessment Scale (ESAS) 4
Brief Pain Inventory (BPI) 4
EuroQol 5D (EQ-5D) 3
Townsend Functional Assessment Scale (TFAS) 3
Frankel Classiﬁ  cation (Neurological status) 3
Functional Living Index: Cancer (FLIC) 2
Hospital Anxiety and Depression Scale (HADS) 2
MSTS 2
Present Pain Intensity scale (PPI) 2
SF-36 2
Spitzer’s quality of life index 2
Aboulaﬁ  a Scoring System 1
Allan Scoring System 1
BR23 1
Fatigue Questionnaire 1
Physical Activity (Functional Classiﬁ  cation 
of the New York Heart Association)
1
Prostate Cancer Speciﬁ  c Quality of 
Life Instrument (PROSQOLI)
1
Toronto Extremity Salvage Score (TESS) 1Journal of Pain Research 2008:1 56
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MSTS, TESS, ESAS, TFAS, RSCL), which include pain-
related questions. Of the two remaining studies, one used 
a performance score while the other used an evaluation of 
neurological function and study-designed questionnaire 
evaluating ambulation.
Performance evaluation
Forty-three percent of the studies (n = 20) measured perfor-
mance status in addition to QOL. The ECOG was the most 
commonly employed (n = 15 [75%]), however the KPS 
was also used (n = 4 [20%]). Lee and colleagues (2000) 
used the Functional Classiﬁ  cation of the New York Heart 
Association to evaluate performance status and measure 
QOL. Helwig and colleagues (1997) utilized the KPS alone 
to evaluate QOL while Fernandez-conde and colleagues 
(1997) evaluated QOL using the KPS and monitoring anal-
gesic consumption.
Conclusion
Quality of life in patients with bone metastases is increas-
ingly considered an essential outcome for clinical trials and 
patient management and therefore good assessment tools are 
of increasing importance. In recent years, a vast number of 
QOL instruments have been developed, including several 
instruments for the general cancer population. However, to 
date, none are speciﬁ  c to the problems associated with bone 
metastases.
Research in the ﬁ  eld of bone metastases has focused on 
pain and its associated outcomes. However, QOL is affected 
by many factors other than pain, including limited mobility, 
reduced performance, side effects and impaired role func-
tioning. Hence a wider range of end-points are required with 
greater sensitivity than those currently employed (Barton 
et al 2001).
From this review, there is increased evidence that an 
instrument incorporating pain from bone metastases along 
with other issues arising from skeletal complications as 
well as psychosocial domains is needed to improve the 
understanding of QOL in patients with bone metastases. 
Recently, Androver and colleagues (2005) developed a 
35-item questionnaire using patient cohorts from different 
cancer centers in Spain. The domains identiﬁ  ed were: pain, 
daily activities, mobility, energy/vitality, adjustment and 
coping, sexual activities, feelings, and health perception. 
However, this instrument has yet to be validated in different 
ethnic and cultural backgrounds. Another effort to develop 
a bone module across different countries that is coordinated 
by the EORTC-QLG is also currently underway.
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